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ABSTRACT
Type III CRISPR systems synthesise cyclic oligoad-
enylate (cOA) second messengers in response to vi-
ral infection of bacteria and archaea, potentiating an
immune response by binding and activating ancil-
lary effector nucleases such as Csx1. As these ef-
fectors are not specific for invading nucleic acids, a
prolonged activation can result in cell dormancy or
death. Some archaeal species encode a specialised
ring nuclease enzyme (Crn1) to degrade cyclic tetra-
adenylate (cA4) and deactivate the ancillary nucle-
ases. Some archaeal viruses and bacteriophage en-
code a potent ring nuclease anti-CRISPR, AcrIII-1, to
rapidly degrade cA4 and neutralise immunity. Homo-
logues of this enzyme (named Crn2) exist in type III
CRISPR systems but are uncharacterised. Here we
describe an unusual fusion between cA4-activated
CRISPR ribonuclease (Csx1) and a cA4-degrading
ring nuclease (Crn2) from Marinitoga piezophila. The
protein has two binding sites that compete for the cA4
ligand, a canonical cA4-activated ribonuclease activ-
ity in the Csx1 domain and a potent cA4 ring nuclease
activity in the C-terminal Crn2 domain. The cA4 bind-
ing affinities and activities of the two constituent en-
zymes in the fusion protein may have evolved to en-
sure a robust but time-limited cOA-activated ribonu-
clease activity that is finely tuned to cA4 levels as a
second messenger of infection.
INTRODUCTION
Type III CRISPR systems have class 1 effector complexes
that utilize CRISPR RNA (crRNA) to detect RNA from
mobile genetic elements (MGE) such as viruses. This tar-
get RNA binding results in the activation of the Cas10 sub-
unit, which commonly harbours two active sites: an HD
nuclease domain for ssDNA cleavage (1–3) and a PALM
polymerase domain that cyclises ATP to generate cyclic
oligoadenylate (cOA) molecules (4–7). cOA acts as a second
messenger in the cell, signalling infection and activating a
range of auxiliary defence enzymes such as the ribonuclease
Csx1/Csm6 (8–10) or the DNA nickase Can1 (11) by bind-
ing to a CRISPR-associated Rossman fold (CARF) sens-
ing domain. Once activated, these enzymes degrade both
host and invading nucleic acids in the cell, which can re-
sult in viral clearance (i.e. immunity) or lead to cell dor-
mancy or even death (akin to Abortive Infection) (12). De-
tection of 1 viral RNA by the Sulfolobus solfataricus type
III-D CRISPR system can lead to the generation of 1000
molecules of cyclic tetra-adenylate (cA4), equivalent to an
intracellular concentration of 6 M cA4, which is sufficient
to fully activate the Csx1 ribonuclease (13).
The potency and high amplification factor inherent in
type III cA4 signalling necessitates a mechanism to clear
cA4 from the cell––otherwise cells could be driven to ‘com-
mit suicide’ unnecessarily. In S. solfataricus, cells express
a specialised catalytic variant of a CARF-domain protein
named ‘CRISPR-associated ring nuclease 1’ (Crn1) that
binds and slowly degrades cA4, returning cells to a basal,
uninfected state (14). The CARF domains of some mem-
bers of the Csm6 family have also been shown to have ring
nuclease activity, slowly degrading cA4 and thus acting as
self-limiting ribonucleases (9,15). More recently, a potent
ring nuclease enzyme of viral origin has been identified that
acts as an anti-CRISPR (Acr) by rapidly degrading cA4 to
circumvent type III CRISPR immunity (16). The enzyme,
AcrIII-1, is a small dimeric protein unrelated to the CARF
domain that uses an active site histidine residue to ensure
higher catalytic efficiency (16). Biochemical and modelling
studies have revealed that AcrIII-1, which is widespread in
archaeal viruses and bacteriophage, efficiently deactivates
Csx1 in vitro (17).
Homologues of AcrIII-1 are also found in association
with type III CRISPR systems in some genomes, where they
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have been predicted to function in the host defence against
MGE. In this context, the enzyme has been named Crn2
(CRISPR-associated ring nuclease 2) (16). We previously
noted an unusual (so far, unique) example of a Crn2 gene
fused to a Csx1 ribonuclease in the type III CRISPR lo-
cus of the organism Marinitoga piezophila (16), and here-
with we term this gene product Csx1–Crn2 (Figure 1). The
M. piezophila CRISPR locus includes a type III-B effector,
an RNA-guided Argonaute enzyme (18) and an uncharac-
terised CARF-RelE protein that may be activated by cOA
to cleave ribosomal A-site mRNA (19). Sequence analy-
sis suggests that Csx1–Crn2 consists of a canonical Csx1
protein, including an N-terminal CARF domain for cOA
sensing and HEPN (Higher Eukaryotes, nucleotide sens-
ing) ribonuclease domain, fused to a Crn2 domain at the C-
terminus (Figure 1B; Supplementary Figure S1). The 563 aa
protein is predicted to form a dimer as dimerization is fun-
damental to the structure and function of both constituent
domains, and a structural model generated by Swissmodel
(17) using the templates Csx1 (PDB 6R7B) and AcrIII-1
(PDB 6SCF) is shown in Figure 1C.
Here, we express, purify and characterise the Csx1–Crn2
protein, revealing cA4-activated ribonuclease activity asso-
ciated with the Csx1 domain and a potent cA4 ring nuclease
activity catalysed by the Crn2 domain – the first cellular ring
nuclease of this family to be studied. Biochemical analysis
of the wild-type and engineered variant forms of the enzyme
allow the mechanism of this self-limiting antiviral defence
enzyme to be delineated.
MATERIALS AND METHODS
Cloning and expression
For cloning, a synthetic gene (g-block) encoding the
Csx1–Crn2 protein, codon optimised for Eschericia coli,
was purchased from Integrated DNA Technologies (IDT),
Coralville, USA, and cloned into the vector pV5HisTev
(20) between the NcoI and BamHI sites. Competent DH5
cells were transformed with the construct and sequence in-
tegrity confirmed by sequencing (Eurofins Genomics). A
single conservative mutation (V177L) in a variable region
of the protein was noted in the cloned gene but was not
deemed problematical. The plasmid was transformed into
E. coli C43 (DE3) cells for protein expression. Two liters
of LB culture was grown at 37◦C to an OD600 of 0.3 with
shaking at 180 rpm. Protein expression was induced with 0.4
mM Isopropyl -D-1-thiogalactopyranoside and cells were
grown at 37◦C overnight before harvesting by centrifuga-
tion at 4000 rpm (Beckman Coulter Avanti JXN-26; JLA8.1
rotor) at 10◦C for 10 min.
Protein purification
Expression and purification of Sulfolobus islandicus rod-
shaped virus 1 gp29 (AcrIII-1) has been described previ-
ously (16). For Csx1-Crn2 purification, the cell pellet was
resuspended in four volumes equivalent of lysis buffer con-
taining 50 mM Tris–HCl 7.5, 0.5 M NaCl, 10 mM imida-
zole and 10% glycerol supplemented with EDTA-free pro-
tease inhibitor tablets (Roche; 1 tablet per 100 ml buffer)
and lysozyme (1 mg/ml). Cells were lysed by sonication (six
times 1 min with 1 min rest intervals on ice) and the lysate
was centrifuged at 40 000 rpm (70 Ti rotor) at 4◦C for 30
min. The lysate was filtered (0.45 m) and then loaded onto
a 5 ml HisTrap FF Crude column (GE Healthcare) equili-
brated with wash buffer containing 50 mM Tris–HCl pH
7.5, 0.5 M NaCl, 30 mM imidazole and 10% glycerol. Un-
bound protein was washed away with 20 column volumes
(CV) of wash buffer prior to elution of his-tagged protein
using a linear gradient (holding at 10% for 3 CV, and 50%
for 3 CV) of elution buffer containing 50 mM Tris–HCl
pH 7.5, 0.5 M NaCl, 0.5 M imidazole and 10% glycerol.
SDS-PAGE was carried out to identify fractions containing
the protein of interest, and relevant fractions were pooled
and concentrated using a 30 kDa molecular weight cut-off
centrifugal concentrator (Merck). The his-tag was removed
by incubating concentrated protein overnight with Tobacco
Etch Virus (TEV) protease (1 mg per 10 mg protein) while
dialyzing in buffer containing 50 mM Tris–HCl pH 7.5, 0.5
M NaCl, 30 mM imidazole and 10% glycerol at room tem-
perature. The protein with his-tag removed was filtered (0.45
m) and isolated using a 5 ml HisTrapFF column, elut-
ing the protein using 4 CV wash buffer. Cleaved protein
was filtered (0.45 m) and further purified by size-exclusion
chromatography (Superdex S200 26/60; GE Healthcare) in
buffer containing 20 mM Tris pH 7.5, 0.25 M NaCl using
an isocratic gradient. After SDS-PAGE, fractions contain-
ing protein of interest were concentrated and protein was
aliquoted and stored at −80◦C.
Variant enzymes were generated using the QuickChange
Site-Directed Mutagenesis kit as per manufacturer’s in-
structions (Agilent technologies), verified by DNA sequenc-
ing and purified as for the wild-type protein.
RNase assays
The RNA oligonucleotide A1 was purchased from IDT
and RNA labeling was carried out as described previ-
ously (4). For RNA degradation assays, 50 nM radiola-
belled RNA A1 was incubated with Csx1-Crn2 (5 or 10
M dimer) with 100 M of cyclic oligoadenylate (cA3,
cA4 or cA6) in Reaction buffer (20 mM MES pH 6.5, 150
mM NaCl, 1 mM EDTA, 1 mM DTT and 0.06 U/l
SUPERase•In RNase Inhibitor) for 30 min (or other in-
dicated timepoints), at 50◦C. Reactions were quenched by
adding phenol–chloroform–isoamyl alcohol (Ambion) and
vortexing. For single-turnover RNA cleavage kinetics ex-
periments, a mix of 50 nM radiolabelled RNA A1 and
100 M cA4 was prepared in pH 6.5 reaction buffer as
above and pre-warmed at 50◦C for 5 min. Addition of
pre-warmed enzyme (10 M dimer Csx1–Crn2 or its vari-
ants) started the reaction. At indicated times, 10 l of the
reaction was taken and quenched by adding to phenol–
chloroform and vortexing. Subsequently, the deproteinised
RNA cleavage products were mixed (1:1) with 100% for-
mamide xylene–cyanol loading dye and separated by de-
naturing polyacrylamide gel electrophoresis (PAGE; 20%
acrylamide, 7 M urea, 1× TBE, 45◦C, 3000 V) for 2 h.
Following the electrophoresis, the gels were phosphorim-
aged at −70◦C overnight. For RNA kinetic analysis, sub-
strate RNA and degradation products were quantified us-
ing the Bio-Formats plugin of ImageJ as distributed in the
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Figure 1. The atypical type III CRISPR system of M. piezophila. (A) CRISPR locus of M. piezophila (NCBI accession NC 016751) includes genes
encoding a complete type III-B (Cmr1–6, Cas6) gene cluster, adaptation proteins Cas1 and Cas2, argonaute, and two uncharacterised CARF-domain
proteins: CARF-RelE and Csx1-Crn2. (B) Cartoon of the Csx1-Crn2 protein highlighting the N-terminal Csx1 ribonuclease and C-terminal Crn2 ring
nuclease components. (C) Structural model of Csx1–Crn2. The active site residues of the HEPN ribonuclease (R397, H402) and ring nuclease (H495) are
shown in spheres. Domain colouring is as for part B. Although the structures of the Csx1 and Crn2 domains are predicted with high confidence, their
relative orientation is not known and the model shown here represents just one possible conformation. (D) SDS-PAGE analysis of purified recombinant
Csx1Crn2 wild-type and variants.
Fiji package and a background signal was subtracted as de-
scribed previously (20). Fraction cleaved was calculated for
every time point and fitted via GraphPad Prism 8 to an ex-
ponential graph Y = Y0 + (Plateau – Y0) *(1 – exp(-K*x))
with Y0 fixed to 0 (one phase association).
A1 oligo: 5′-AGGGUAUUAUUUGUUUGUUUCU
UCUAAACUAUAAGCUAGUUCUGGAGA
cA4 pre-incubation assay
Prior to the addition of RNA, 10 M enzyme dimer WT
or its variant H495A were mixed with 10, 50 or 100 M
cA4 in reaction buffer and incubated for 10 min at 50◦C.
To start the reaction, ∼50 nM radiolabelled RNA A1 was
added and the reactions were incubated for a further 30 min
at the same temperature before quenching and analysis as
described above.
cA4 degradation assays
Radiolabelled cyclic oligoadenylates were generated enzy-
matically using type III-D effector complex of S. solfatar-
icus, as described previously (14). For cA4 cleavage assay,
∼200 nM radiolabeled cA4 was incubated with either 1 or
5 M dimer Csx1–Crn2 or its variants in reaction buffer at
50◦C, over a set of time points as indicated in the relevant
figure legends. As a positive control, cA4 and 1 M AcrIII-
1 SIRV1 gp29 were assayed for 1 min. At the desired time
points, 10 l of the reaction was removed and quenched
by adding to phenol–chloroform and vortexing. Depro-
teinised products were then further isolated by chloroform-
isoamyl alcohol extraction (Sigma-Aldrich) for thin-layer
chromatography. As a negative control, cA4 was incubated
to the end-point of each experiment.
Multiple-turnover kinetics
For multiple turnover kinetics of cA4 cleavage, a reaction
mix composed of 256 M unlabelled cA4, ∼100 nM radi-
olabelled cA4 and varying concentration of enzyme dimer
(160, 320, 480, 640, 1280, 2560 and 5120 nM) in Reaction
buffer was prepared and incubated at 50◦C. Addition of pre-
warmed enzyme to the reaction mix started the reaction.
At certain time points, 10 l of the reaction was removed,
quenched, and extracted as described above. RNA cleav-
age was then visualised by denaturing PAGE and the frac-
tion of RNA cut was quantified and initial rates were cal-
culated. Initial rates were plotted against substrate concen-
tration and fitted to a linear equation on GraphPad Prism
8 to obtain the multiple-turnover rate of cA4 cleavage by
Csx1–Crn2.
Thin-layer chromatography (TLC)
TLC was carried out as described previously (16). In brief,
a glass chamber was pre-warmed for 1 h at 38◦C and then
left to humidify with 0.5 cm of TLC buffer (100 ml; 0.2 M
ammonium bicarbonate pH 9.2, 70% ethanol, H2O) for a
further 45 min. 1 l of sample was spotted 1 cm from the
bottom of a 20 cm × 20 cm silica gel on TLC Aluminium
foil plate (Supelco Sigma-Aldrich) and the TLC plate was
placed into the humidified glass chamber, sealed, and the
buffer was allowed to migrate up the plate for ∼3 h at 35◦C
(until the migration front reached ∼17 cm). The TLC plate
was then air dried and phosphorimaged overnight.
Electrophoretic mobility shift assay
For the binding assay, 10 nM radioactively-labelled cA4 was
incubated with Csx1–Crn2 variants H495A, H129W and
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S452Y at varying concentrations in binding buffer contain-
ing 20 mM Tris–HCl pH 7.5, 150 mM NaCl and 2 mM
MgCl2 supplemented with 2 M Ultrapure Bovine Serum
Albumin (Invitrogen) for 10 min at 25◦C. Following the in-
cubation, samples were mixed with an equivalent volume of
20% (v/v) glycerol and equal volumes were run on a native
polyacrylamide gel (15% acrylamide, 1× TBE) at 250 V, 30
W and 28◦C for ∼3 h. Binding was visualized by phospho-
rimaging at −70◦C overnight.
RESULTS
Expression and purification of Csx1–Crn2
A synthetic gene (g-block) encoding the M. piezophila
Csx1–Crn2 protein, codon optimised for expression in Es-
cherichia coli, was cloned into the pEV5hisTev plasmid (20),
allowing expression of the recombinant protein with a cleav-
able N-terminal polyhistidine tag. The protein was puri-
fied to near homogeneity by a combination of immobilized
metal affinity and size exclusion chromatography (Figure
1D). Enzyme variants with mutations targeted to the active
site of the Csx1 ribonuclease (H402A) or the Crn2 enzyme
(H495A) were expressed and purified as for the wild-type
enzyme.
The N-terminal domain of Csx1-Crn2 is a cA4-activated ri-
bonuclease
Type III CRISPR systems typically synthesize a range of
cOA molecules with a ring size varying from 3–6 (4–7,21).
We first wished to determine the identity of the activator for
Csx1–Crn2 by incubating the enzyme with an RNA sub-
strate (RNA A1) in the presence of cA3, cA4 or cA6. Only
cA4 activated the ribonuclease activity of the enzyme (Fig-
ure 2A), consistent with the predicted structural similarity
to the cA4-activated Csx1 protein of S. islandicus (10). A
variant enzyme with a mutation targeted to the HEPN ri-
bonuclease active site (H402A) was inactive for RNA degra-
dation, but the H495A variant with a mutation targeted to
the Crn2 active site appeared more active than the wild-
type enzyme (Figure 2B). Overall, these data confirmed that
the HEPN domain of Csx1-Crn2 was responsible for RNA
cleavage and suggested that the ring nuclease activity might
serve to limit the ribonuclease activity.
We noted that the RNA substrate was processed in the
absence of cA4 activator by trimming of a small number of
nucleotides from the 3′ end (e.g. Figure 2A lane 2). This ac-
tivity was abolished in the H495A variant (e.g. Figure 2B
lane c1) suggesting that the ring nuclease domain is capable
of processing the 3′ ends of RNAs independent of cA4 ac-
tivation. This RNase activity is reminiscent of the CARF-
family protein Csx3, which has been described as a dead-
enylase (22) and has parallels with the observed binding of
S. islandicus Csx1 to the 3′ tetra-adenylate tails of mRNA
(23). The 3′-terminus of the RNA A1 substrate consists of
four purine nucleotides (GAGA). While cA3 and cA6 did
not support target RNA degradation, they did block RNA
trimming (Figure 2A), suggesting they still compete with
RNA for binding to the Crn2 active site.
The C-terminal domain of Csx1–Crn2 is a highly active ring
nuclease specific for cA4 degradation
Having established that cA4 was the activator of the Csx1
domain, we tested the ability of the Crn2 domain to de-
grade cA4 in vitro (Figure 3A). Rapid degradation of cA4 to
linear A2>P (di-adenylate with a 3′-cyclic phosphate) was
observed within the first minute of the assay, followed by
a slower conversion of A2>P to A2-P (di-adenylate with a
3′-phosphate). Overall, the reaction rate and products were
highly reminiscent of the AcrIII-1 enzymes studied previ-
ously (16). A variant enzyme with a mutation targeted to the
predicted active site histidine of the Crn2 domain (H495A)
did not degrade cA4, confirming the Crn2 domain as the
site for ring nuclease activity. The single-turnover reaction
kinetics of the Csx1–Crn2 ring nuclease activity were too
rapid to quantify, suggesting a catalytic rate constant of the
order of 10 min−1. To explore this more fully, we carried out
a series of kinetic experiments under multiple turnover con-
ditions, using 256 M cA4 substrate and varying the con-
centration of Csx1–Crn2 from 0.16 nM to 5.12 M (Figure
3B). The initial reaction rate at each enzyme concentration
was quantified and plotted, yielding data that could be fit-
ted with a linear fit of slope 8.8 ± 0.3 min−1 (Figure 3B).
Assuming that the enzyme is saturated at 256 M cA4, this
affords an estimation of kcat for the ring nuclease activity of
about 9 min−1––in good agreement with the single turnover
data for Csx1–Crn2 and other related ring nucleases (16).
Thus, the Crn2 active site is a highly active ring nuclease ca-
pable of rapid, multiple-turnover degradation of the cA4 ac-
tivator and does not appear to be significantly rate-limited
by substrate binding or product release.
Deactivation of the ring nuclease activity enhances ribonucle-
ase activity of Csx1–Crn2
Having established the activities of the Csx1 and Crn2
domains individually, we next wished to investigate how
the two enzymatic domains collaborate to potentiate cA4-
activated RNA degradation. Firstly, we pre-incubated the
wild-type or H495A variant forms of the enzyme with cA4
for 10 min, then added wild-type enzyme together with ra-
diolabelled substrate RNA to assess Csx1 activity (Figure
4A). When the (ring nuclease inactive) H495A variant was
used in the pre-incubation, robust RNA degradation by
Csx1 was observed at all three cA4 concentrations tested
(Figure 4B). However, following pre-incubation with wild-
type Csx1-Crn2, RNA degradation was minimal except for
the highest concentration of cA4 (100 M). This experiment
demonstrated that Csx1–Crn2 can self-deactivate (in bulk
terms) by degrading cA4 in the ring nuclease site.
We next quantified RNA degradation over time in a reac-
tion including 10 M Csx1–Crn2 (wild-type or H495A vari-
ant), 100 M cA4 and ∼50 nM radioactively labelled sub-
strate RNA. The wild-type enzyme displayed more rapid
initial kinetics, degrading approximately 50% of the RNA
within 2 min, but quickly reached a plateau after which
RNA was not further degraded (Figure 4C). In contrast,
the H495A variant, which is unable to degrade cA4, had a
slower rate constant but completely degraded all the sub-
strate RNA in the course of the 30 min incubation. The
slower initial rate may be due to cA4 sequestration by the
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Figure 2. The Csx1 domain of Csx1–Crn2 is a cA4-activated ribonuclease. (A) RNase assay to determine activator of Csx1 domain. Phosphorimage of
denaturing PAGE shows the radiolabeled RNA A1 (50 nM) assayed with 1 M Csx1–Crn2 dimer and a cyclic activator (100 M): cA4 (cyclic tetra-
adenylate), cA3 (cyclic tri-adenylate), or cA6 (cyclic hexa-adenylate). Samples were incubated at 50◦C for 30 min. The control lanes c1 and c2 show the
assay in the absence of activator or the absence of enzyme, respectively. The data are representative of three technical replicates. (B) Phosphorimage of
denaturing PAGE visualising degradation of radiolabeled RNA by Csx1-Crn2 or its variant H402A (10 M dimer) when activated by cA4 (100 M) at
50◦C (time points are 1, 2, 4, 10, 15, 30 min). Control reactions carried out to the end-point of each assay without cA4 (c1) or without enzyme (c2) are
shown. The data is representive of three technical replicates.
Figure 3. Csx1–Crn2 rapidly degrades cA4. (A) Phosphorimage of thin-layer chromatography (TLC) visualising degradation of radiolabelled cA4 (∼200
nM) by Csx1-Crn2 or its H495A variant (1 M dimer) at 50◦C over time (1, 10, 60 min). Control reactions incubating radiolabelled cA4 with buffer
(c1, negative control) for 60 min or with 1 M AcrIII-1 for 1 min (c2, positive control) are also shown; the data are representative of three technical
replicates. (B) Csx1–Crn2 rapidly degrades cA4 under multiple-turnover conditions. The initial rate of cA4 (256 M) degradation was quantified at different
concentrations of Csx1–Crn2 protein and plotted. A linear function was fitted through the origin and the catalytic rate constant kcat was estimated (kcat =
8.8 ± 0.3 min−1). Each data point is the average of at least three technical replicates and error bars show standard deviation of the mean.
Crn2 binding site, but it is also possible that the H495A mu-
tation results in a reduced specific activity of the Csx1 en-
zyme by unspecified means. Thus, the two active sites have
the ability to cooperate to ensure that cA4-stimulated RNA
degradation is regulated, potentially limiting the cellular re-
sponse to viral infection.
cA4 binding affinity of the Csx1-CARF and Crn2 domains
Next, we wished to understand the interaction between cA4
and the CARF and Crn2 domains of Csx1-Crn2 that bind
the second messenger. We first investigated cA4 binding by
the H495A variant, which can bind but not cleave cA4 in the
Crn2 site, by electrophoretic mobility shift assay (EMSA),
using ∼10 nM radioactively-labeled cA4 (Figure 5B). A
clear gel-shift was observed yielding an apparent KD of
around 20 nM, which is similar to that previously observed
for stand-alone ring nucleases (13). As there are two cA4
binding sites in the protein, we next designed variant en-
zymes to abolish cA4 binding in either the CARF (H129W)
or Crn2 (S452Y) binding sites, guided by the structural
model shown (Figure 5A) and multiple sequence alignment
(Supplementary Figure S1). These bulky amino acid substi-
tutions were predicted to prevent or significantly reduce cA4
binding without destabilising the protein structure (Sup-
plementary Figure S2). The two variants were purified as
for the wild-type protein, and cA4 binding was assessed by
EMSA (Figure 5B). The S452Y variant showed no obvi-
ous binding of cA4, but cleavage of cA4 at high protein con-
centrations (apparent KD ∼ 1 M) suggested that the cA4
binding at the ring nuclease site was strongly reduced but
not abolished. The H129W variant cleaved cA4 into A2>P
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Figure 4. Csx1-Crn2 is an example of a self-limiting ribonuclease. (A) The scheme of the pre-incubation experiment. (B). Denaturing PAGE shows degra-
dation of radiolabelled RNA (50 nM) by WT or its H495A variant (10 M dimer) that were pre-incubated with 10, 50 or 100 M cA4 at 50◦C for 10 min
prior to addition of radiolabelled RNA A1, followed by incubation for a further 30 min. A set of control reactions in the same conditions but lacking cA4
(c1), enzyme (c2) or both (c3) are shown. The data represent the results of three technical replicates. (C). Quantification of fraction of RNA degraded by
either Csx1-Crn2 (WT) or its H495A variant (10 M dimer) at 50◦C over time. The results were fitted with an exponential equation and estimated rates
of RNA cleavage are shown (WT, k = 0.56 ± 0.11 min−1, plateau = 0.54 ± 0.03; H495A, k = 0.11 ± 0.01 min−1, plateau = 1.02 ± 0.03). The data points
are the average of three technical replicates and error bars show standard deviation of the mean.
at a concentration of 20 nM enzyme, consistent with high
affinity binding and cleavage at the Crn2 site. Overall, these
data suggest that the CARF domain has a weaker intrinsic
affinity for cA4 than the ring nuclease domain. Otherwise,
we would have expected to see higher affinity binding of cA4
by the CARF domain of the S452Y variant. However, we
cannot rule out the possibility that the S452Y mutation re-
sults in weaker binding of cA4 by the CARF domain.
We also tested the ring nuclease and RNA cleavage ac-
tivities of the two variant enzymes (Figure 5C, D). As pre-
dicted, the S452Y variant had a severely reduced, although
not abolished, ring nuclease activity––consistent with the
EMSA result. The H129W variant was a fully active ring
nuclease, ruling out a model whereby the two cA4 binding
sites communicate to control cA4 degradation. As expected,
the H129W variant had no cA4-activated RNase activity,
confirming that this variant does not bind cA4 in the CARF
domain. Neither of the variants targeting the ring nuclease
domain had a discernible effect on the activity of the Csx1
ribonuclease.
DISCUSSION
The importance of cyclic nucleotide signalling in prokary-
otic anti-viral defence systems is an emerging paradigm. Ex-
amples include cA4 and cA6 for type III CRISPR (5,6), cA3
for the HORMA-DncV-NucC system (24,25) and a variety
of cyclic dinucleotides synthesised by diverse CBASS en-
zymes (26,27). Viruses have a clear imperative to degrade
these molecules and circumvent immunity, but it is increas-
ingly apparent that cellular immune systems also need a
mechanism to turnover these second messengers if they
are to prevent runaway toxicity and cell death (13). For
type III CRISPR systems at least, immunity rather than
abortive infection may be the modus operandi, as mecha-
nisms exist to ‘kill the messenger’. Ring nucleases that de-
grade cA4 include the dedicated enzymes and self-limiting
ribonucleases based on the CARF domain (9,14,15) and
the DUF1874 family whose members include the viral anti-
CRISPR AcrIII-1 and putative cellular Crn2 proteins (16).
Crn2 ring nucleases have been detected in diverse bacte-
rial genomes associated with type III CRISPR defence but
not yet characterised. Here, we focussed on an unusual fu-
sion of a Csx1 ribonuclease and Crn2 ring nuclease from
Marinitoga piezophila, whose genome also has a CRISPR-
associated Argonaute enzyme and an uncharacterised, pre-
dicted cA4-activated RelE toxin (Figure 1). We have demon-
strated that the fused protein does indeed combine the ac-
tivities of a canonical cA4-activated Csx1 ribonuclease and
a highly active ring nuclease. The ring nuclease activity, with
a kcat of 9 min−1, is on a par with the highly active viral Acr
enzymes (16) and ∼20-fold more active than Crn1, suggest-
ing that cellular Crn2 enzymes are not always ‘de-tuned’ to
act more slowly than their viral cousins. The level of ring
nuclease activity required in a cell may of course depend
on the concentration of cA4 synthesised by different type
III CRISPR systems. Furthermore, the existence of a fusion
between Csx1 and Crn2 means that the relative concentra-
tions of the two enzymes can not be varied in response to
infection––they are of necessity fixed at 1:1. This is a distinct
advantage when exploring the logic of a complex system as
the relative concentrations of the effectors are defined with
certainty.
These observations raise the intriguing question of how
the two activities collaborate to provide appropriate levels
of immunity. Our in vitro analyses clearly demonstrate that
the ring nuclease activity limits, but does not abolish, the
cA4-activated ribonuclease activity of Csx1 (Figure 4). One
can rationalise this by assuming that the two enzymes com-
pete for binding of cA4, and that once activated, the Csx1
enzyme can catalyse multiple rounds of RNA cleavage be-
fore the activator dissociates. Only then is there a chance
to degrade it at the Crn2 active site. The balance between
ribonuclease and ring nuclease enzyme activities will thus
largely be determined by their relative affinities for cA4. Per-
haps surprisingly, we observe that the Crn2 domain binds
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Figure 5. Dissection of cA4 binding and catalysis by Csx1–Crn2. (A) Cartoon representation of Csx1–Crn2 showing sites targeted by mutagenesis. (B).
Electrophoretic mobility shift assay (EMSA) showing binding of radiolabelled cA4 (∼10 nM) by Csx1-Crn2 variants (0.001, 0.01, 0.02, 0.03, 0.04, 0.05,
0.06, 0.08, 0.1, 1.0, 10.0 and 20.0 M, respectively). On each gel is a control reaction (c) with cA4 in the absence of protein. The ring nuclease defective
variant H495A bound cA4 with an apparent dissociation constant around 20 nM. The S452Y variant, which was designed to abolish cA4 binding by
the ring nuclease domain, had a severe binding defect, with cA4 degradation apparent at high protein concentrations. The H129W variant, designed to
abolish cA4 binding in the CARF domain, showed cA4 degradation starting from around 20 nM enzyme. The data are representative of three technical
replicates. (C) TLC showing degradation of cA4 (200 nM) by wild-type and variant enzymes (5 M dimer) at 50◦C. A time-course of 10 s, 1 min and 10
min was carried out and a control reaction (c) incubating buffer with radiolabeled cA4 for 10 min is also shown. The H495A variant was inactive as shown
previously. The H129W and H402A variants targeting the CARF and HEPN (Csx1) domains, respectively, had normal ring nuclease activity. Whereas
the S452Y variant targeting the Crn2 domain had strongly reduced activity, consistent with weaker binding of cA4 by the Crn2 domain. (D) Denaturing
PAGE showing cleavage of radiolabelled substrate RNA (100 nM) by Csx1-Crn2 and variants (5 M dimer) and 100 M cA4 at 50◦C. RNA cleavage
was examined at two time-points (5 & 30 min) and control reactions incubating radiolabelled RNA in buffer (c1) or RNA and protein in the absence of
cA4 activator (c2) for 30 min are also shown. The H129W and H402A variants were inactive as expected. The data are representative of three technical
replicates.
cA4 much more tightly than the CARF domain (apparent
KD ∼20 nM and > 1 M, respectively). This suggests that
the RNase activity of Csx1 will only be licensed once cA4
concentrations reach high M levels in the cell. This is not
necessarily a limitation, as the large degree of signal ampli-
fication generated by type III CRISPR systems can result
in a 6 M concentration of cA4 in cells detecting only 1
viral RNA, generated over 20–30 min (4,13). Indeed, this
characteristic could be beneficial in shielding the cell from
inappropriate/transient firing of cA4 production due to self-
targetting events, for example. It should also be noted that
a second cA4-activated defence enzyme is encoded by the
CRISPR locus of M. piezophila––a predicted RelE enzyme
that may be licensed by cA4 binding to cleave mRNA under-
going translation. Thus the Crn2 ring nuclease may need to
function in the deactivation of two enzymes that could be
toxic to the cell if not restrained. Overall, this study high-
lights the pressing need for prokaryotic cells to have a mech-
anism to remove cyclic nucleotide second messengers effi-
ciently in circumstances where abortive immunity is not the
desired outcome, or to dampen down any spurious activa-
tion of the pathway in the absence of phage infection.
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White,M.F. (2018) Ring nucleases deactivate Type III CRISPR
ribonucleases by degrading cyclic oligoadenylate. Nature, 562,
277–280.
15. Athukoralage,J.S., Graham,S., Grüschow,S., Rouillon,C. and
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